Scientists are closely watching SARS-CoV-2 to track mutations and see if it's developed into different strains. So, has it?

A 2025 NJBIZ In the Lead Family-Owned Businesses honoree, the chain now has 14 other locations across three states. Tommy’s ...

Bengaluru-based Biomoneta has achieved a significant first, becoming the inaugural Indian healthtech firm to secure US-FDA ...

While mRNA vaccines trigger potent initial immune responses, emerging data suggest they do not generate durable plasma cells, ...

Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a ...

Every winter, respiratory viruses, especially influenza, SARS-CoV-2 and RSV, put huge pressure on health care systems ...

H3N2 has actually been circulating since around 1968 with annual genetic changes designed to evade our immune systems. Its ...

That plus 12 other thoughts about Dr. Vinay Prasad’s recent memo.

This report provides useful evidence that EABR mRNA is at least as effective as standard S mRNA vaccines for the SARS-CoV-2 booster vaccine. Although the methodology and the experimental approaches ...

FDA chief medical officer Vinay Prasad told reporters that the agency would be changing its vaccine approval process.

Individuals with post-COVID condition report lower work ability and greater impairments in work performance for 3 years after infection than those without the condition.

The World Health Organization (WHO) has released a new strategic plan for the management of coronavirus disease threats, ...